Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-06-26
2007-06-26
Owens, Amelia A. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S316000, C514S397000, C514S406000, C514S320000, C546S187000, C546S196000, C548S311400, C548S364400, C549S390000
Reexamination Certificate
active
10602745
ABSTRACT:
Novel non-psychotropic cannabinoids are disclosed and pharmaceutical compositions comprising these novel compounds are described for preventing neurotoxicity, neuroinflammation, immune or inflammatory disorders comprising as active ingredient the stereospecific (+) enantiomer, having (3S,4S) configuration of Δ6tetrahydrocannabinol type compounds. The compositions are particularly effective in alleviating and even preventing neurotoxicity due to acute injuries to the central nervous system, including mechanical trauma, compromised or reduced blood supply as may occur in cardiac arrest or stroke, or poisonings. They are also effective in the treatment of certain inflammatory disorders and chronic degenerative diseases characterized by neuronal loss and chronic pain including neuropathic pain.
REFERENCES:
patent: 5521215 (1996-05-01), Mechoulam et al.
patent: 5538993 (1996-07-01), Mechoulam et al.
patent: 5635530 (1997-06-01), Mechoulam et al.
patent: 5872148 (1999-02-01), Makriyannis et al.
patent: 5932610 (1999-08-01), Shohami et al.
patent: 6096740 (2000-08-01), Mechoulam et al.
patent: 6162829 (2000-12-01), Burstein
patent: 6166066 (2000-12-01), Makriyannis et al.
patent: 6284788 (2001-09-01), Mittendorf et al.
Barth, F., “Cannabinoid Receptor Agonists And Antagonists”, Exp. Opin. Ther. Patents, vol. 8: pp. 301-313, (1998).
McIntosh, T.K., “Novel Pharmacologic Therapies In The Treatment Of Experimental Traumatic Brain Injury: A Review”, Journal of. Neurotrauma , vol. 10:, pp. 215-244 (1993).
Rogawski, M.A., “Therapeutic Potential Of Excitatory Amino Acid Antagonists: Channel Blockers And 2,3-Benzodiazepines”, Trends in Pharmacology. Science., vol. 14: pp. 325-331, (1993).
Danbolt, N.C., “Glutamate Uptake”, Progress in Neurobiology , vol. 65: 1 pp. 1-105 (2001.).
Mechoulam, R., et al., “Endocannabinoids”, Eur. Journal of. Pharmacology,, vol. 359: pp. 1-18 (1998).
Williams, C.S. et al., “Prostaglandin Endoperoxide Synthase: Why Two Isoforms?”, American . Physiological.Society,, vol. 270: pp. G393-400 (1996).
Golden, B.D.et al., “Selective Cyclooxygenase-2 Inhibitors”, Rheumatic Diseases Clinics of North America., vol. 25: pp. 359-378 (1999).
Smalley, W.E. et al., “Colorectal Cancer And Nonsteroidal Anti-Inflammatory Drugs”, Adv. Pharmacology., vol. 39: pp. 1-20 (1997).
Lipsky, P.E., “Specific COX-2 Inhibitors In Arthritis, Oncology, And Beyond: Where Is The Science Headed?”, J. Rheumatology., vol. 26: Suppl 56: pp. 25-30 (1999).
Ross, R., “Atherosclerosis, An Inflammatory Disease”, New England Journal of. Medicine., vol. 340, No. 2: pp. 115-126 (1999).
Mechoulam, R., et al., “Synthesis Of The Individual, Pharmacologically Distinct, Enantiomers Of A Tetrahydrocannabinol Derivative”, Tetrahedron Asymmetry, vol. 1: No. 5, pp. 315-318, (1990).
Mechoulam, R. et al., “Enantiomeric Cannabinoids: Stereospecificity Of Psychotropic Activity”, Experientia, vol. 44: pp. 762-764 (1988).
Eshhar, N. et al., “Kainyl-Bovine Serum Albumin: A Novel Ligand Of The Kainate Sub-Type Of Glutamate Receptor With A Very High Binding Affinity”, Brain Res. , vol. 476: pp. 57-70 (1989).
Belayev, L. et al., “HU-211, A Novel Noncompetitive N-Methyl-D-Aspartate Antagonist, Improves Neurological Deficit And Reduces Infarct Volume After Reversible Focal Cerebral Ischemia In The Rat”, Stroke, vol. 26: pp. 2313-2320 (1995).
Nonaka S. et al., “Neuroprotective Effects Of Chronic Lithium On Focal Cerebral Ischemia In Rats”, NeuroReport, vol. 9: pp. 2081-2084 (1998).
Montoya, C.P. et al., “The “Staircase Test”: A Measure Of Independent Forelimb Reaching And Grasping Abilities In Rats”, Journal. Neuroscience, Methods. , vol. 36: pp. 219-228 (1991).
Sharkey, J. et al., “Tacrolimus (FK506) Ameliorates Skilled Motor Deficits Produced By Middle Cerebral Artery Occlusion In Rats”, Stroke, vol. 27, No. 12,: pp. 2282-2286 (1996).
Liberatore, G.T. et al., “Inducible Nitric Oxide Synthase Stimulates Dopaminergic Neurodegeneration In The MPTP Model Of Parkinson Disease”, Nature Medicine, vol. 5, No. 12: pp. 1403-1490.
Duvdevani, R. et al., “Graded Crush Of The Rat Optic Nerve As A Brain Injury Model: Combining Electrophysiological And Behavioral Outcome”, Restorative. Neurology and Neuroscience. , vol. 2: pp. 31-38 (1990).
Skene, J.H.P. et al.,., “Characteristics Of Growth-Associated Polypeptides In Regenerating Toad Retinal Ganglion Cell Axons”, J. Neuroscience, vol. 1, No. 4: pp. 419-426 (1981).
Leor, J.et al., “An Experimental Model Examining The Role Of Magnesium In The Therapy Of Acute Myocardial Infarction”, American. Journal. Cardiology., vol. 75: pp. 1292-1293 (1995).
Fink George
Garzon Aaron
Owens Amelia A.
Pharmos Corporation
Winston & Strawn LLP
LandOfFree
Non-psychotropic cannabinoids does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Non-psychotropic cannabinoids, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Non-psychotropic cannabinoids will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3844155